Clinical Trials Logo

Filter by:
NCT ID: NCT00813644 Active, not recruiting - Endoscopic Skills Clinical Trials

A Study of Flexible Ureteroscopy Proficiency After Training on the Uromentor Simulator

UROSIMULATOR08
Start date: December 2008
Phase: N/A
Study type: Observational

The development of virtual reality (VR) simulators is changing surgical endoscopic education. The translation of VR skills into clinical endoscopic proficiency has been shown by M.PEARLE. The improvement in performing endoscopic tasks after VR training was evaluated on a cadaver. Our goal is to evaluate the performance of novice endoscopists at the operating room by a randomized controlled study comparing subjects randomized to train on a the "UroMentor" simulator to those without VR training.

NCT ID: NCT00813475 Not yet recruiting - Diabetes Clinical Trials

Effect of Diabetes Control on Outcome in Hospitalized Patients: A National Israeli Study

Start date: January 2009
Phase: N/A
Study type: Interventional

To test whether tight glucose control is associated with better clinical outcome compared to less-tight control, among diabetic patients hospitalized in internal medicine wards.

NCT ID: NCT00813436 Recruiting - Schizophrenia Clinical Trials

The Effect of Intranasal Administration of Oxytocin on Empathic Abilities.

20070766
Start date: May 2008
Phase: Phase 2
Study type: Interventional

Empathy constitutes one prominent ability of social cognition, which represents the human capability of understanding mental state of the other, and responding in sympathetic way. Two sets of theoretical mechanisms were designed in order to explain how empathy is possible. Theory of Mind (ToM)and Simulation.People who suffer from schizophrenia frequently exhibit social dysfunction, preventing them of a normal integration in healthy human environments. Recently it had been discovered that impairment in empathy and a specific impairment in effective TOM are mostly associated with the social malfunctioning of people who suffer from schizophrenia. One of the biological substances most connected to social cognition is the neuromodulator Oxytocin. Among its known involvement in uterine contractions and lactating females, numerous recent studies have found an indispensable role for Oxytocin in various complex prosocial behaviors such as maternal behavior, attachment, partner preference and trust. In the proposed study, we plan to examine the influence of a single dose of intranasal Oxytocin on the two primary mechanisms of empathy, namely mentalizing (Theory of Mind) and Simulation, both in healthy people and in people who suffer from schizophrenia.

NCT ID: NCT00812175 Completed - Clinical trials for Carcinoma, Hepatocellular

Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib

GIDEON
Start date: January 2009
Phase: N/A
Study type: Observational

In this international non-interventional study safety and clinical data concerning the treatment of patients suffering from Hepatocellular Carcinoma (HCC) will be collected.

NCT ID: NCT00811265 Completed - Prostate Cancer Clinical Trials

Safety Evaluation of ExAblate MRgFUS for Prostate Cancer

Start date: January 2009
Phase: Phase 1
Study type: Interventional

Evaluate the safety, compatibility and imaging quality of the ExAblate MRgFUS system.

NCT ID: NCT00811161 Recruiting - Clinical trials for Wrinkles or Damaged Skin Condition

An Open Label Study to Evaluate the Efficacy of Airgent in Treating Damaged and Wrinkled Skin

Start date: May 2009
Phase: N/A
Study type: Interventional

The primary objective of this study is to Evaluate the effectiveness of treatment of wrinkles or damaged skin with the Airgent device. The secondary objective of this study are to: - Evaluate subjects' satisfactory of the treatment. - Demonstrate the safety of the Airgent treatment by evaluation of adverse events.

NCT ID: NCT00811018 Terminated - Clinical trials for Pulmonary Arterial Hypertension

A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension

STRIDE-3
Start date: March 2003
Phase: Phase 3
Study type: Interventional

This is a multi-center, open-label study of sitaxsentan sodium 100 mg taken orally once daily by subjects with PAH until sitaxsentan, in a particular country or region, is commercially available for the treatment of PAH or the study is closed.

NCT ID: NCT00810693 Completed - Clinical trials for Pulmonary Hypertension

A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)

PATENT-1
Start date: December 17, 2008
Phase: Phase 3
Study type: Interventional

The aim of the study is to assess the efficacy and safety of different doses of BAY63-2521 given orally for 12 weeks, in patients with symptomatic Pulmonary Arterial Hypertension (PAH).

NCT ID: NCT00810433 Completed - Lower Back Pain Clinical Trials

A Clinical Study of the GO-LIF® Approach for Lumbar Spinal Fixation

Start date: February 2009
Phase: N/A
Study type: Interventional

The purpose of this study is to collect data regarding the safety and feasibility of the GO-LIF procedure for spinal fixation and stabilization, in conjunction with conventional approaches for interbody lumbar fusion. This is in order to allow for evidence-based comparison to pedicle-screw-based techniques as described in the literature.

NCT ID: NCT00810199 Completed - Clinical trials for Rheumatoid Arthritis

A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment

Start date: March 2009
Phase: Phase 3
Study type: Interventional

This 2 arm study will compare 2 treatment strategies based on tocilizumab in combination with methotrexate or placebo in patients with moderate to severe rheumatoid arthritis. Patients receiving methotrexate treatment will be randomized to receive either a) tocilizumab 8 mg intravenous (iv) every 4 weeks + methotrexate orally (po) weekly or b) tocilizumab 8 mg iv every 4 weeks + placebo po weekly. After the first 24 weeks of blinded treatment, treatment adjustments (increase or decrease of treatment intensity) may be introduced at intervals, based on response. The anticipated time on study treatment is up to 3 years, and the target sample size is approximately 470 patients.